Jerald Boseman, MD
Nephrology · Orem, UTNPI 1801807144
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $585 of the $654 with a category attached, or 89.4%. It is spread thinly across 8 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $322 and has fallen 94.4% since, to $18 in 2023. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.
Across 26 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$154
- Amgen$141
- Planmeca USA, Inc.$104
- Otsuka America Pharmaceutical, Inc.$103
- Nxstage Medical, Inc.$69
- AstraZeneca$53
- plus $29 from 2 others
What the payments were for
- Food & beverage$58589%
- Education$6911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 4 | $154 |
| Amgen(2 entities) | 8 | $141 |
| Planmeca USA, Inc. | 1 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $103 |
| Nxstage Medical, Inc. | 1 | $69 |
| AstraZeneca(2 entities) | 3 | $53 |
| Vifor Pharma, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 4 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PLANMECA PROMAX$104
How this compares
$654 in reported general payments places this provider in the 40th percentile of 74 nephrology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 180 | $134,686 |
| JardianceEmpagliflozin | 70 | $54,878 |
| KerendiaFinerenone | 23 | $14,760 |
| Sevelamer Carbonate | 48 | $6,375 |
| Losartan Potassium | 193 | $2,103 |
| Sodium Polystyrene Sulfonate | 24 | $2,006 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,743 |
| Amlodipine Besylate | 192 | $1,621 |
| Hydralazine Hcl | 82 | $1,320 |
| Labetalol Hcl | 17 | $1,156 |
| Torsemide | 31 | $1,149 |
| Lisinopril | 111 | $1,099 |
| Potassium Chloride | 65 | $1,007 |
| Calcium Acetate | 14 | $811 |
| Mycophenolate Mofetil | 16 | $676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $53 | $134,686180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 74 nephrology providers in Utah.
Other nephrology in Orem
- Sanjiv AnandSouth Salt Lake$144K
- Alfred CheungSalt Lake City$132K
- Donald KohanSalt Lake City$119K
- Anitha VijayanMurray$118K
- Fuad ShihabSalt Lake City$83K
- William BaragerProvo$13K
- Srinivasa BeddhuSalt Lake City$8K
- George JaradSaint George$7K
- Carlos MercadoSt George$5K
- Carlos LeonSt George$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.